| Gene symbol | IL2 | Synonyms | IL-2, TCGF, lymphokine | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q27 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 2 | ||||
| Gene symbol | TNF | Synonyms | DIF, TNF-alpha, TNFA, TNFSF2, TNLG1F | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | tumor necrosis factor | ||||
| GTO ID | GTC4006 |
| Trial ID | NCT04695327 |
| Disease | Solid Tumor |
| Altered gene | E1A|TNFa|IL-2 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | TILT-123|igrelimogene litadenorepvec |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors |
| Year | 2021 |
| Country | Finland |
| Company sponsor | TILT Biotherapeutics Ltd. |
| Other ID(s) | TILT-T115|2020-001778-31 |
| Vector information | |||||||||||||||
|
|||||||||||||||
| Cohort 1 | |||||||||
|
|||||||||